News in brief: Oral therapy for SMA on the PBS; Ocrelizumab advice on neutropenia; Soccer players ‘heading’ toward neurodegenerative disease

Oral therapy for SMA listed on the PBS Australians with spinal muscular atrophy (SMA) types 1, 2 or 3a who are aged 18 years or under when treatment begins now have PBS subsidised access to risdiplam (Evrysdi). The oral daily therapy for SMA is a less invasive treatment option for patients compared to spinal injections ...

Already a member?

Login to keep reading.

© 2021 the limbic